Received Dec 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | — |
Post-Measles-Mumps-Rubella Vaccination Optic Perineuritis; This Literature (Spontaneous) report has been received from the authors of a published article, titled as stated below. Information has been received from the authors in a literature spontaneous article referenced above concerning to 70 -year-old Male patient. The patient's concurrent conditions included hypertension, prediabetes, coronary artery disease, hypercholesterolemia, obstructive sleep apnea, obesity, asthma, persisting cough, and hearing difficulties. The patient's past medications were not reported. The patient's concomitant medications included tamsulosin, atorvastatin, budesonide formoterol, irbesartan, baby aspirin, multivitamin, and prednisone. The patient had not received adequate immunization with the Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection (M-M-R II) vaccine during his childhood. Following a measles outbreak at the start of 2025, his plans to visit an affected region prompted preventative Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection (M-M-R II) immunization. On 03-March-2025, he had a medical encounter for a new cough diagnosed as mild asthma exacerbation and received a prednisone prescription as treatment On 19-Mar-2025, the was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection (M-M-R II) (strength, dose, route, lot number and expiration date were not provided) as preventative immunization (Prophylaxis). On 18-APR-2025, the patient receevd the second dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection (M-M-R II) (strength, dose, route, lot number and expiration date were not provided) as preventative immunization (Prophylaxis) On 21-May-2025 (also reported as: Approximately 9 weeks following administration of the first MMR dose), the patient experienced acute vision loss in the right eye described as a black spot in the central vision with blurriness, moving pinpoint flashes of light, and bright out lines surrounding objects, which lasted for approximately 15 minutes. This was associated with a dull headache, and he denied experiencing any vertigo, migraine, seizures, dizziness, severe headaches, scalp tenderness or jaw claudication. Two days later the episode of positive visual phenomena recurred, followed by self-resolution and a remaining dull headache with decreased vision. Three days later, on 24-May-2025, the patient received a T1 fat- suppressed gadolinium-enhanced magnetic resonance imaging (MRI) orbits in an outside facility, showing circumferential thickening with enhancement of the right optic nerve sheath and inflammatory changes of the intraconal fat suggestive of right optic perineuritis (OPN), therefore the patient was admitted and on admission to the Hospital, the following day (25-May-2025), laboratory investigations showed elevated inflammatory markers including erythrocyte sedimentation rate (ESR) of 23 mm/hr and C-reactive protein (CRP) of 1.93 mg/dL. Also, he had an elevated white blood cell count with neutrophilic predominance, a low hematocrit, and elevated HbA1c, serum testing for syphilis, bartonella, Lyme, myelin oligodendrocytic glycoprotein (MOG), anti-nuclear antibody (ANA), and anti- neutrophilic cytoplasmic antibody (ANCA) were negative and serum angiotensin converting enzyme (ACE) was normal, and a chest radiograph was clear. The patient was started on a course of intravenous (IV) methylprednisolone 1 g daily for 3 days then transitioned to 500 mg q12h. He reported complete resolution of visual symptoms with only a mild remaining headache by the second day of treatment. He was discharged on the fourth day on 27-may-2025 on oral prednisone 60 mg daily and was tapered without recurrence. On presentation to our clinic approximately 7 weeks after discharge, visual acuity measured 20/25 in the right eye (OD) and 20/50 in the left eye (OS). There was a relative afferent pupillary defect (RAPD) OD. The extraocular motility exam was normal. Slit lamp biomicroscopy was normal. There was an inactive inferonasal chorior etinal scar OD, noted from 3 years prior. Optical coherence tomography (OCT) global measure ments and automated perimetry (Humphrey visual field (HVF) 242) was normal. The Outcome of Post-Measles-Mumps-Rubella Vaccination Optic Perineuritis was recovering. The reporter considered the event of Optic perineuritis to be related to Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection (M-M-R II). A key criterion supporting a post-MMR etiology was the temporal association between vaccination and symptom onset. A copy of the published article is attached as further documentation of the patient's experience. Literature Report.
Asthma; Coronary artery disease; Hard of hearing; Hypercholesterolemia; Hypertension; Obesity; Obstructive sleep apnea; Prediabetes
tamsulosin; budesonide formoterol; irbesartan; baby aspirin; multivitamin; prednisone; atorvastatin; sterile diluent
Test Date: 20250524; Test Name: Magnetic resonance imaging (MRI); Result Unstructured Data: showing circumferential thickening with enhancement of the right optic nerve sheath and inflammatory changes of the intraconal fat suggestive of right optic peri neuritis (OPN); Test Name: Extensive laboratory investigations; Test Result: Negative; Result Unstructured Data: Were negative for common infectious and inflammatory etiologies; Comments: Were negative for common infectious and inflammatory etiologies; Test Date: 20250525; Test Name: erythrocyte sedimentation rate (ESR); Result Unstructured Data: elevated, at 23 mm/h; Comments: elevated; Test Date: 20250525; Test Name: C-reactive protein (CRP); Result Unstructured Data: elevated at 1.93 mg/dL; Comments: elevated; Test Date: 20250525; Test Name: white blood cell count; Result Unstructured Data: elevated, neutrophilic predominance.; Test Date: 20250525; Test Name: hematocrit; Result Unstructured Data: Low; Test Date: 20250525; Test Name: HbA1c; Result Unstructured Data: elevated; Test Date: 20250525; Test Name: Serum testing for syphilis; Test Result: Negative; Test Date: 20250525; Test Name: Serum testing bartonella; Test Result: Negative; Test Date: 20250525; Test Name: Serum testing for Lyme; Test Result: Negative; Test Date: 20250525; Test Name: myelin oligodendrocyte glycoprotein (MOG); Test Result: Negative; Test Date: 20250525; Test Name: anti-nuclear antibody (ANA); Test Result: Negative; Test Date: 20250525; Test Name: anti-neutrophilic cytoplasmic antibody (ANCA); Test Result: Negative; Test Date: 20250525; Test Name: Serum angiotensin converting enzyme (ACE); Result Unstructured Data: normal; Test Date: 20250525; Test Name: chest radiograph; Result Unstructured Data: clear; Test Date: 2025; Test Name: visual acuity; Result Unstructured Data: 20/25 in the right eye (OD) and 20/50 in the left eye (OS). There was a relative afferent pupillary defect (RAPD) OD; Test Date: 2025; Test Name: extraocular motility exam; Result Unstructured Data: normal; Test Date: 2025; Test Name: Slit lamp bio microscopy; Result Unstructured Data: normal, There was an inactive inferonasal Chori retinal scar OD, noted from 3 years prior; Test Date: 2025; Test Name: Optical coherence tomography (OCT) global measurements; Result Unstructured Data: normal; Test Date: 2025; Test Name: automated perimetry (Humphrey visual field (HVF) 242); Result Unstructured Data: normal